Daiichi Sankyo Co., Ltd.: Innovation leads the future

Daiichi Sankyo Company Limited (TYO: 4568) is a world-renowned multinational original pharmaceutical group, known for its outstanding R&D capabilities and extensive medical product lines. As a company dedicated to human health, Daiichi Sankyo has not only made remarkable achievements in the field of pharmaceutical research and development, but also made continuous breakthroughs in the development of medical devices and related products. Its headquarters is located in Tokyo, Japan, and its official website is www.daiichisankyo-hc.co.jp .

Daiichi Sankyo's mission is to improve the quality of life of patients around the world through innovative drugs and medical services. This goal drives the company's global business expansion and research investment. As a pharmaceutical company with a profound historical heritage, Daiichi Sankyo has always been at the forefront of the industry, promoting the advancement of medical science, and has won wide recognition and trust around the world.

The origin and development of the company

The history of Daiichi Sankyo can be traced back to the late 19th century. In 1899, Sankyo Pharmaceutical Co., Ltd. was established, and then renamed "Sankyo Pharmaceutical" in 1900. After more than a century of development, Sankyo Pharmaceutical has gradually grown into one of the leading pharmaceutical companies in Japan and the world. In 2005, Sankyo Pharmaceutical merged with Daiichi Pharmaceutical to form Daiichi Sankyo Co., Ltd., further consolidating its position in the global pharmaceutical industry.

Since its establishment, Daiichi Sankyo has always focused on new drug research and development and technological innovation. The company has continuously improved its competitiveness by integrating the resources and technological advantages of the two companies. In particular, Daiichi Sankyo's research and development results in the fields of cardiovascular diseases, tumor treatment, and anti-infective drugs have been highly praised by the international community. In addition, the company is also actively deploying emerging technology fields such as gene therapy and precision medicine, striving to occupy a leading position in the future development of medicine.

Core Business Areas

Daiichi Sankyo's core business covers pharmaceutical research and development, production and sales, as well as the development of medical devices and related products. The following is a detailed introduction to the company's main business areas:

1. Drug R&D and production

As a pharmaceutical company with R&D at its core, Daiichi Sankyo has a strong product portfolio in multiple therapeutic areas. The company focuses on developing innovative drugs to address unmet medical needs. The following are some key areas:

• Cardiovascular diseases: Daiichi Sankyo is a leader in the treatment of cardiovascular diseases such as hypertension and hyperlipidemia. For example, the antihypertensive drugs and statins developed by the company have been widely used in clinical practice.
• Tumor treatment: In recent years, the company has made major breakthroughs in the research and development of anti-cancer drugs, especially in targeted therapeutic drugs for breast cancer, lung cancer and other fields.
• Anti-infective drugs: Daiichi Sankyo has also accumulated rich experience in the field of antibiotics and antiviral drugs, providing important support for the global fight against infectious diseases.
• Central nervous system diseases: The company has developed a series of effective drugs for mental illnesses such as depression and anxiety to help patients improve their quality of life.

In addition to traditional drugs, Daiichi Sankyo is also actively exploring emerging fields such as biologics and gene therapy, striving to provide patients with more diverse treatment options.

2. Medical devices and related products

Daiichi Sankyo not only focuses on drug research and development, but also has made achievements in the field of medical devices and related products. The company has launched a number of innovative medical devices for diagnosis, treatment and rehabilitation through independent research and development or cooperation with other companies. These products include but are not limited to:

• Portable medical devices used to monitor a patient's health.
• Surgical auxiliary instruments improve surgical efficiency and safety.
• Rehabilitation training equipment helps patients restore their physical functions.

By combining pharmaceuticals with medical devices, Daiichi Sankyo is able to provide comprehensive solutions for medical institutions and patients.

Globalization strategy and international cooperation

As a multinational company, Daiichi Sankyo is well aware of the importance of globalization and is continuously expanding its global influence by establishing overseas branches, acquiring local companies, and establishing partnerships.

At present, Daiichi Sankyo has established R&D centers and production bases in Asia, Europe, North America and other regions to ensure that it can quickly respond to the needs of different markets. At the same time, the company actively participates in international clinical trials and cooperates with the world's top research institutions and universities to jointly promote the development of medical science.

It is worth mentioning that Daiichi Sankyo attaches great importance to cooperation with local companies. For example, in the Chinese market, the company has established strategic alliances with a number of pharmaceutical companies to jointly develop drugs that meet the needs of Chinese patients. This cooperation model not only promotes technical exchanges, but also brings more business opportunities to the company.

Sustainable development and social responsibility

Daiichi Sankyo has always regarded sustainable development and social responsibility as an important part of corporate development. The company fulfills its commitment to society in many ways:

• Environmental protection: Daiichi Sankyo is committed to reducing carbon emissions and waste generation in the production process and promoting the concept of green manufacturing.
• Employee Care: The company provides employees with a good working environment and development opportunities, and encourages a diverse and inclusive culture.
• Public welfare: Daiichi Sankyo actively participates in various public welfare activities, supports the development of medical and health care, and helps disadvantaged groups obtain better medical services.

In addition, Daiichi Sankyo has established a special fund to support medical research and education projects to cultivate future medical talents.

Official website: www.daiichisankyo-hc.co.jp

The official website of Daiichi Sankyo ( www.daiichisankyo-hc.co.jp ) is an important window to understand the company information. The website not only displays the history, vision and core values ​​of Daiichi Sankyo, but also provides a wealth of business information and scientific research trends.

Visitors can obtain the following content through the official website:

• Company profile and organizational structure.
• The latest research and development results and product information.
• Business distribution and cooperation cases in the global market.
• Sustainability reporting and social responsibility activities.
• Investor relations materials, including financial statements and shareholder meeting announcements.

In addition, the official website also has a career development zone, which provides recruitment information and application channels for talents who are interested in joining Daiichi Sankyo. Both industry professionals and the general public can use this platform to gain a deeper understanding of Daiichi Sankyo and its contributions to the pharmaceutical field.

Looking ahead

With the aging of the global population and the rising incidence of chronic diseases, the pharmaceutical industry is facing unprecedented opportunities and challenges. Daiichi Sankyo will continue to uphold the concept of "innovation leads the future", increase R&D investment, expand business territory, and bring more benefits to patients around the world.

In the next few years, Daiichi Sankyo plans to focus on the following development directions:

• Accelerate research into gene and cell therapies to explore the possibility of curative drugs.
• Deepen digital transformation and use artificial intelligence and big data technologies to optimize drug research and development processes.
• Strengthen relationships with global partners to jointly address public health challenges.
• Expand business coverage in emerging markets, especially in Asia and Africa.

In short, Daiichi Sankyo Co., Ltd. is not only a leader in the global pharmaceutical industry, but also an important force in promoting the progress of human health. With its outstanding R&D capabilities, global vision and strong sense of social responsibility, Daiichi Sankyo will continue to write a brilliant chapter in the future.